Evolus (EOLS) Long-Term Deferred Tax (2022 - 2023)
Evolus' (EOLS) quarterly Long-Term Deferred Tax came in at $83.3 million in Q4 2023, up 574.53% YoY from $12.3 million in Q4 2022, and up 574.53% on a QoQ basis from $12.3 million in Q4 2022.
Evolus (EOLS) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Evolus (EOLS) has 2 years of Long-Term Deferred Tax data on file, last reported at $83.3 million in Q4 2023.
- Quarterly Long-Term Deferred Tax rose 574.53% year-over-year to $83.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $83.3 million (up 574.53% YoY) and the FY2023 annual result came in at $83.3 million, up 574.53% from the prior year.
- Long-Term Deferred Tax improved to $83.3 million in Q4 2023, from $12.3 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $83.3 million in Q4 2023 to a low of $12.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 83.26 Mn |
| Dec 31, 2022 | 12.34 Mn |